Charles River Portfolio

Charles River takes the guesswork out of CNS research, delivering world-class services that span the drug development continuum. Check out some of our recent CNS news below.

Four New Rodent Pain Models Now Available
08/28/2013
Our new pain models focus on neuropathic, inflammatory and chronic joint pain indications and provide quantitative behavioral endpoints for developing new pain medications.  They assist researchers in assessing and increasing translatability between discovery and first-in-human studies.

Translational Imaging of In Vivo CNS Models
07/09/2013
Imaging is used routinely in clinical studies and is becoming the only truly translatable, noninvasive biomarker to human CNS diseases. In addition to behavioral testing and biochemical markers, neuroanatomical and functional imaging is an inherent component of preclinical in vivo CNS efficacy studies at Charles River.

Neurological Biomarkers in Efficacy Studies Now Available
06/13/2013
Biomarkers support the findings from in vivo efficacy studies involving behavioral and imaging analysis, and they give more in-depth information about the molecular and cellular targets that are being aimed at in various disease models. Biomarkers also aid in piecing together the translational aspects that may exist between the actual human disease and the animal model of the disease being employed.

High-Throughput Screening for CNS Lead Compounds In Vivo
05/13/2013
We have established an in vivo screening platform to provide fast and cost-effective screening of compound effects on motor behavior and brain functionality for the study for central nervous system diseases.

Combine Surgical and Preconditioning Services for Study-Ready Animal Models
02/28/2013
Charles River offers animal models with combined surgeries or services (e.g., feeding studies with tissue collection) to help meet the ever-changing needs of our customers.

Biological Materials Used to Induce Disease and Create Validated CNS Study Models
02/18/2013
We are employing various biological materials and biosimilars in both in vivo and CNS efficacy studies in order to create and validate study models of neurological and psychological diseases. These therapeutic interventions include administration of proteins, RNA and stem cells.

Introducing Our Fully Validated Preclinical In Vivo Schizophrenia Model
02/11/2013
As part of our ongoing development program in the areas of neurology and psychiatry, we are pleased to introduce an updated and fully validated preclinical in vivo model for the study of compounds and therapies aimed at combating the cognitive and negative symptoms of schizophrenia.